SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access — SPECTAlung  

Any Stage of Any Thymic Malignancy Clinical Trial

Official title: SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

Status Completed

Clinical Trial Summary

SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Any Stage of Any Thymic Malignancy
• Any Stage of Lung Cancer (Any Histotype)
• Any Stage of Malignant Pleural Mesothelioma
• Mesothelioma
• Mesothelioma, Malignant
• Neoplasms
• Thoracic Neoplasms

• NCT number: NCT02214134
• Study type: Observational [Patient Registry]
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Status: Completed
• Start date: May 22, 2015
• Completion date: May 12, 2021